Cutaneous necrosis complicating the injection of pegylated interferon α-2b in a patient with chronic hepatitis C

Acta Dermatovenerologica Croatica

Volumn 16, Issue 1, 2008, Pages 35-37

  Rosina, Paolo ^a   Pugliarello, Silvia ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Cutaneous necrosis; Hepatitis C; Interferon alfa; Ribavirin; Side effects

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID DERIVATIVE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONFERENCE PAPER; HEPATITIS C; HUMAN; HUMAN TISSUE; INJECTION SITE NECROSIS; LABORATORY TEST; MALE; SKIN BIOPSY; SKIN NECROSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NECROSIS; POLYETHYLENE GLYCOLS; SHOULDER; SKIN;

EID: 44349133327     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
2. Sookoian S, Neglia V, Castano G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999;135:1000-1.
3. Chang L, Liranzo M, Bergfeld W. Cutaneous side effects associated with interferon-alpha therapy: a review. Cutis 1995;56:144.
4. Gallina K, Brodell RT, Naffah F, Nedorost S. Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C. J Drugs Dermatol 2003;2:63-7.
5. Wang Y, Youngster S, Grace M, Bausch J, Bordens R, Wyss D. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Rev 2002;54:547-70.
6. Kurzen H, Petzoldt D, Hartschuh W, Jappe U. Cutaneous necrosis after subcutaneous injection of polyethylene-glycol-modified interferon alfa. Acta Derm Venereol 2002;82:310-2.
7. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002;147:1142-6.
8. Bessis D, Charron A, Rouzier-Panis R, Blatiere V, Guilhou JJ, Reynes J. Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient. Eur J Dermatol 2002;12:99-102.
9. Rogers CJ, Romagosa R, Vincek V. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. J Am Acad Dermatol 2004; 50:640-50.
10. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005;141:865-8.
11. Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004;140:215-7.
12. Sickler JB, Simmons RA, Cobb DK, Shermann KE. Cutaneous necrosis associated with interferon α-2b. Am J Gastroenterol 1998;93:463-4.
13. Konohana A, Hasegawa Y, Kobayshi T. Cutaneous ulceration resulting from intramuscular injections of interferon alpha. J Am Acad Dermatol 1996;35:788-9.
14. Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roe E, Alomar A. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol 2005;53:62-6.
15. Christian MM, Diven DG, Sanchez RL, Soloway RD. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. J Am Acad Dermatol 1997;37:118-20.